Sentence: This review focuses on the activity and toxicity of the time-limited combination of venetoclax plus rituximab for the treatment of relapsed or refractory CLL , presenting clinical trial results and data from correlative studies , with the aim of highlighting the strengths of this treatment approach and discuss weaknesses and possible areas of improvement .
Drug combination annotation:
[{'class': 'POS', 'spans': ['venetoclax', 'rituximab'], 'is_context_needed': True}]